Denis Corin, President of Q BioMed (QBIO:OTC), explains how this biomedical acceleration and development company moves forward in the industry.
Q BioMed is a biotechnology accelerator, and what that means is we take a really close look at many assets out there in the biotech and pharmaceuticals space, look for those that are undervalued or under recognized and we bring significant resources to those assets to help them materialize and accelerate their development to a point of inflection when there is an IPO or sale or actually just revenue generating.
We’ve closed on our first asset, which is in the glaucoma space. So huge blue sky opportunity there, there are no new drugs in this sector for the last 20 years. Recently we announced our second asset acquisition or license deal with a revenue ready asset that we expect to be able to generate revenue within the first 12 months of closing the deal.
Our product pipeline is designed to span a broad range of healthcare sectors. So we are not pigeonholing ourselves into drug development or medical devices. We’ve a broad spectrum and broad developmental timeline so that investors can feel confident that they have an investment in both early stage and late stage technologies and see their investment grow as each of those milestones are met in multiple therapeutic areas.
The Company is very well-structured, very young company. We only have eight-and-a-half million shares outstanding. Management ownership is 35 to 40 percent, it’s a very tightly held, well-structured organization. And we think that will obviously grow and provide value for shareholders as they invest in the development and the milestones that we achieve.